1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Interview: Mereo All Set For Key Setrusumab Data

 
• By Kevin Grogan

Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.

Q4 2019
End of the year will be pivotal for Mereo • Source: Shutterstock

Mereo BioPharma Group PLC is gearing up for a pivotal fourth quarter which will see the readout of data on the UK company's key asset, setrusumab for brittle bone disease.

In an interview with Scrip, CEO Denise Scots-Knight noted that earlier this year, Mereo posted positive six-month data from the open-label arm of its Phase IIb ASTEROID trial of setrusumab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.